BAT Reddit Mentions | ChartExchange

TL;DR -- the real issue is that 78 events have happened, but there were 126 participants. 63 in the control group (BAT, of whatever combination), 63 in the treatment group (SLS GPS). Statistically, it is impossible that 48 living subjects have survived this long due to BAT (78 'events' + 48 living = 126). GPS is the only explanation for 48 participants remaining.
Gemini response:
# Phase 2 Findings (The Benchmark)
In the open-label Phase 2 study of galinpepimut-S (GPS) in AML patients in **CR2** (who were in second remission but ineligible for or refusing allogeneic stem cell transplant), the results showed a strong statistical divergence from historical standard of care:
* **GPS Arm Median Overall Survival (mOS):** **21.0 months** (at a median follow-up of 30.8 months).
* **Historical / Contemporaneous Standard of Care (BAT):** **5.4 months** ($p < 0.02$).
* **Immunogenicity:** 64% to 80% of patients demonstrated confirmed WT1-specific CD4+ and CD8+ T-cell immune responses, which correlated with the prolonged survival times.
# Does REGAL Extend Life Expectancy Better Than BAT?
Whether REGAL conclusively beats modern BAT across the board comes down to the comparison between the **Phase 2 baseline** and **modern Phase 3 trial dynamics**:
|**Metric / Setting**|**Historical Standard of Care**|**Modern BAT in CR2 (e.g., VEN+AZA)**|**SELLAS GPS (Phase 2 Data)**|**REGAL (Phase 3 Blinded Interim)**|
|:-|:-|:-|:-|:-|
|**Median OS**|**\~5.4 months**|**\~6 to 10 months**|**21.0 months**|**>13.5 months** (pooled/blinded)|
|**1-Year Survival**|$< 20\\%$|\~25% – 35%|**\~60%+**|Ongoing|
|**Primary Limitation**|Rapid refractory relapse|Toxicities / acquired resistance|Small sample size ($N \\approx 20$)|Unblinded final readout pending|
# Key Clinical Drivers & Nuance in CR2
1. Maintenance vs. Active Rescue: Patients in CR2 have cleared detectable leukemia for a second time, but residual leukemic stem cells (MRD) almost inevitably cause a rapid, fatal relapse without an allogeneic bone marrow transplant. Traditional chemotherapy or hypomethylating agents cause cumulative bone marrow toxicity. GPS acts as an immunotherapy/vaccine aimed at preventing relapse by training T-cells to destroy remaining WT1-expressing leukemia cells without suppressing bone marrow recovery.
2. The BAT Benchmark Shift: The Phase 2 trial compared GPS to historical controls on older regimens (palliative low-dose cytarabine or single-agent hypomethylating agents, mOS$\\sim 5.4$ months). In the Phase 3 REGAL trial, investigators were permitted to use modern combinations like Venetoclax + Azacitidine (VEN+AZA). While VEN+AZA improves salvage remissions, patients in CR2 who cannot undergo a transplant still face a heavy risk of relapse within 6 to 10 months on average.
3. Trial Status: At the interim analysis (60 events), the Independent Data Monitoring Committee (IDMC) confirmed GPS passed futility and safety benchmarks, showing pooled trial survival exceeding 13.5 months. GPS showed superior survival relative to the 5.4-month historical baseline in Phase 2; the upcoming final analysis of the 80-event REGAL readout will provide the definitive answer on whether it statistically outperforms modern physician's-choice BAT in a randomized head-to-head setting.
To answer this clearly, we look at the probability in two different ways: **for two specific individual patients**, and **across the entire \~63-patient control group** in the trial.
# 1. For Two Specific Individual Patients
If you pick two specific patients at random who started modern BAT (where individual 28-month survival is $10\\%$ to $15\\%$):
* **At 10% individual odds:** $0.10 \\times 0.10 = \\mathbf{1.0\\%}$ (1 in 100 chance)
* **At 15% individual odds:** $0.15 \\times 0.15 = \\mathbf{2.25\\%}$ (1 in 44 chance)
For any two particular individuals, the odds that both survive past 28 months are low—between **1% and 2.25%**.
# 2. Across the Entire Control Arm (~63 Patients)
In a clinical trial cohort of **63 patients** (the BAT arm in REGAL), each person acts as an independent trial with a $10\\%$ to $15\\%$ chance of reaching 28+ months. Using the **Binomial Distribution**:
* **Expected Survivors:** Out of 63 patients, you expect an average of **6 to 9 survivors** ($63 \\times 0.10 = 6.3$; $63 \\times 0.15 = 9.45$).
* **Odds that AT LEAST 2 Patients Survive:** **98.95% to 99.96%** (virtually guaranteed).
* **Odds that EXACTLY 2 Patients Survive:** **0.22% to 3.16%**.
# What This Means for the Trial Data
* **It is not surprising for BAT to have 2 survivors:** In a group of 63 patients on modern combination therapy, having 2 or more patients reach 28+ months is statistically almost certain ($\\approx 99\\%$).
* **The real statistical constraint is the 48 total living patients:** Because modern BAT only explains about **6 to 9** long-term survivors out of the 48 patients still alive across the entire trial, the remaining **39 to 42 living patients** must belong to the GPS arm.
* **The resulting ratio:** That leaves GPS with roughly **39–42 survivors out of \~63** ($\~62\\%–67\\%$ 28-month survival), compared to BAT's **6–9 survivors out of \~63** ($\~10\\%–15\\%$).

.dark-mode .TYg10j{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .TYg10j{ color: #333333; background-color: white; border: 2px solid #333333; }BATBTCBasic Attention Token / Bitcoincrypto Composite

BATBTC
Basic Attention Token / Bitcoin
crypto Composite